Skip to content
Open access

Shared genetic architecture between premenstrual disorder symptoms and major psychiatric disorders suggests a role for calcium signaling

Oct 2026 · European psychiatry · Vol 69 · 0 citations · 96 references
Medicine

TL;DR

Twenty genetic loci are identified between the S-PMD and MPDs, implicating calcium transmission in the pathogenesis of PMDs, which provides a biological basis for repurposing existing drugs in the treatment of PMD.

Abstract

Abstract Background Major psychiatric disorders (MPDs) and premenstrual disorders (PMDs) are often comorbid, with indications of shared genetic architecture. However, the specific genetic variants underlying this comorbidity remain elusive. The aim of this study was to identify genomic loci shared between MPDs and PMDs, and to assess the functional characteristics of genes mapped to these loci. Methods We used genome-wide association data for symptoms of PMDs (S-PMD, n = 67 068) from the Norwegian Mother, Father and Child Cohort Study (MoBa), and for MPDs (schizophrenia, n = 130 644; bipolar disorder, n = 827 335; major depression, n = 1 918 432) from the Psychiatric Genomic Consortium. Shared genetic loci were identified with the conjunctional false discovery rate (conjFDR). Genes mapped to the identified loci were included in functional and pharmacological gene-set enrichment analyses (GSEAs). Results We identified 20 loci shared between S-PMD and the MPDs, including 19 novel loci for S-PMD (conjFDR<0.05). GSEA revealed genes involved in calcium signaling and neuronal projection pathways. The drug enrichment analysis identified 36 drugs, including riluzole and mianserin, significantly associated with the identified molecular pathways. Conclusions We identified 20 genetic loci shared between the S-PMD and MPDs, implicating calcium transmission in the pathogenesis of PMDs. Together with the drug enrichment results, this provides a biological basis for repurposing existing drugs in the treatment of PMD.

Read PDF

Similar papers

Oct 2026

Epigenomic correlates of co-morbid psychosis in 22q deletion syndrome.

PURPOSE 22q11.2 deletion syndrome (22q11DS) confers one of the strongest genetic risks of psychiatric disorders, with up to 25% of 22q11DS patients developing symptoms of psychosis. The broad phenotypic spectrum, variable deletion size, and lack of a defined pathogenic mechanism make it likely that 22q11DS phenotypes a...

Alexander S. Byrne, S. Goodman, Hannah Nie et al. · 0 citations
Open access Nov 2026

Gene discovery and pleiotropic architecture of multidimensional pain in a genome-wide association study of >1.2 million individuals.

Chronic pain is highly prevalent worldwide, yet its genetic architecture remains to be fully elucidated. Here we leveraged data from 1,235,695 European-ancestry individuals across three biobanks. In a meta-analytic genome-wide association study of multidimensional pain (MP), we identified 343 independent loci, 92 of wh...

S. Toikumo, Christal N. Davis, Zeal Jinwala et al. · 0 citations
Open access Sep 2026

Gender-specific associations between polygenic scores and age-specific risk of psychiatric disorders.

BACKGROUND Polygenic scores (PGS) have been used to quantify genetic liability for psychiatric disorders, but it remains unclear how these scores are associated with age- and gender-specific risk of diagnosis. AIMS To examine associations between disorder-specific PGS and age- and gender-specific risk of psychiatric...

Genona T. Maseras, Dan-Ni Chen, C. Albiñana et al. · 0 citations
Open access Nov 2026

Neurotransmitter-specific polygenic scores dissect clinical heterogeneity in schizophrenia

Schizophrenia (SCZ) is a highly heritable psychiatric disorder characterised by substantial clinical heterogeneity. While global polygenic scores (gPGS) capture genetic liability to SCZ, their ability to explain clinical variability remains limited. Pathway-stratified polygenic scores (sPGS) offer a biologically inform...

P. Ramon-Cañellas, J. Vazquez-Bourgon, B. Crespo-Facorro et al. · 0 citations
Open access Sep 2026

A founder population reveals genetic variation with major effect on serious mental illness

Genetic studies of serious mental illness (SMI, including schizophrenia and bipolar disorder) have implicated two classes of risk variant: common variants1-3, each of small effect but collectively accounting for most population-level risk, and ultra-rare coding variants4,5 which confer large risk in a small number of i...

Greta Gerdes, V. Tozzo, S. Service et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.